NCT07345559 Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock
| NCT ID | NCT07345559 |
| Status | Recruiting |
| Phase | — |
| Sponsor | CMC Ambroise Paré |
| Condition | Cardiogenic Shock |
| Study Type | INTERVENTIONAL |
| Enrollment | 406 participants |
| Start Date | 2026-03-26 |
| Primary Completion | 2029-07-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 406 participants in total. It began in 2026-03-26 with a primary completion date of 2029-07-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cardiogenic shock is a life-threatening condition characterized by inadequate cardiac output, leading to organ hypoperfusion and high mortality. Maintaining mean arterial pressure (MAP) is crucial, but standard targets may be insufficient due to venous congestion. Central venous pressure (CVP) can help assess effective perfusion pressure. This study investigates whether a personalized MAP target adjusted by CVP improves organ function and survival compared to standard MAP management.
Eligibility Criteria
Inclusion Criteria: * Aged ≥18 years * Cardiogenic shock state, according to the consensus definition, * SCAI (Society for Cardiovascular Angiography and Interventions) classification ≥ C * Consent from the patient or close relative / trusted person or emergency inclusion procedure * Benefiting fromciary of a social security scheme Exclusion Criteria: * Catecholamine infusion for more than 24 consecutive hours; * CVP \< 5 mm Hg at inclusion; * MAP \> 70 mmHg at inclusion; * Chronic kidney disease stage G4 (defined by an eGFR between 15-29 ml/min/1.73 m²) or G5 (defined by an eGFR less than 15 ml/min/1.73 m²) according to the KDIGO CKD classification at inclusion; * Chronic dialysis or presence of renal replacement therapy criteria at inclusion ; * Recovered cardiopulmonary arrest within 7 days prior to inclusion; * Patient already on mechanical circulatory support at inclusion before enrollment (patients who receive support after inclusion will not be excluded); * Primary diagnosis of tamponade, pulmonary embolism, or septic shock; * Hypersensitivity to norepinephrine tartrate or to any of the following excipients: sodium chloride, hydrochloric acid or sodium hydroxide water for injectable preparations; * Absence of central venous access; * Known pregnancy or current breastfeeding; * Under legal guardianship, curatorship, or judicial protection.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07345559 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiogenic Shock. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07345559 currently recruiting?
Yes, NCT07345559 is actively recruiting participants. Contact the research team at armand.dessap@aphp.fr for enrollment information.
Where is the NCT07345559 trial being conducted?
This trial is being conducted at Amiens, France, Créteil, France, Massy, France, Neuilly-sur-Seine, France and 7 additional locations.
Who is sponsoring the NCT07345559 clinical trial?
NCT07345559 is sponsored by CMC Ambroise Paré. The trial plans to enroll 406 participants.